Organic Pressurized Fluid Patents (Class 424/45)
  • Publication number: 20140140936
    Abstract: The present invention provides compositions which not only effectively kill a broad spectrum of microorganisms present on surfaces on contact but continue to kill microorganisms for a period of time thereafter.
    Type: Application
    Filed: January 24, 2014
    Publication date: May 22, 2014
    Applicant: Reckitt Benckiser LLC.
    Inventors: Timothy Michael Cusack, Karen McCue, Hubert W. Ulmer
  • Publication number: 20140140935
    Abstract: Disclosed are sprayable, pressurized inanimate surface and air liquid treatment compositions which impart a microbicidal benefit to treated surfaces which compositions comprise (or in certain preferred embodiments may consist essentially of, or may consist of): a copper source material which releases copper ions into the treatment composition, preferably a source of Cu(I) and/or Cu(II) ions; at least one quaternary ammonium compound which provides a microbicidal benefit; a propellant; and, water.
    Type: Application
    Filed: May 18, 2012
    Publication date: May 22, 2014
    Applicant: Reckitt Benckiser LLC
    Inventors: Mohammad Khalid Ijaz, Joseph Rubino, Yun-Peng Zhu
  • Patent number: 8728442
    Abstract: The present invention relates to novel compounds and compositions and the use of them for the control of fungal and bacterial pathogens, insect pests, acari, nematodes and other invertebrate pests including, but not limited to post-harvest and soil diseases, building mold remediation, and seed and grain sanitation.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: May 20, 2014
    Assignee: Bayer CropScience LP
    Inventors: Jorge I. Jimenez, Jonathan S. Margolis, John Kenneth Baird, Sarah F. Lego
  • Publication number: 20140134112
    Abstract: A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.
    Type: Application
    Filed: January 21, 2014
    Publication date: May 15, 2014
    Applicant: Precision Dermatology, Inc.
    Inventors: Mark W. Trumbore, Ronald M. Gurge, Jane C. Hirsh
  • Patent number: 8722652
    Abstract: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3?]-androsta-4,16-dien-3-ol.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: May 13, 2014
    Assignee: Pherin Pharmaceuticals, Inc.
    Inventor: Louis Monti-Bloch
  • Publication number: 20140127141
    Abstract: Disclosed are pressurized surface treatment compositions which impart a microbicidal benefit to treated surfaces which compositions comprise (or in certain preferred embodiments may consist essentially of, or may consist of): a copper source material which releases copper ions into the treatment composition, preferably a source of Cu(I) and/or Cu(II) ions, at least lower alkyl aliphatic monohydric alcohol which independently of other constituents present exhibits a microbicidal effect, a propellant; and, water. The compositions may further optionally include one or more further optional constituents such as a detersive surfactant and/or minor amounts of one or more constituents which impart one or more advantageous technical or aesthetic benefits to the compositions, including one or more detersive surfactants wherein the compositions have pH of at least 5. The compositions exhibit a microbicidal or germicidal or antimicrobial effect on treated inanimate surfaces or when used to treat an airspace, e.g.
    Type: Application
    Filed: May 18, 2012
    Publication date: May 8, 2014
    Applicant: Reckitt Benckiser LLC
    Inventors: Mohammad Khalid Ijaz, Joseph Rubino, Yun-Peng Zhu
  • Patent number: 8715623
    Abstract: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 6, 2014
    Assignee: Novartis AG
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
  • Patent number: 8715624
    Abstract: The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C2-C4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C2-C4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9?-fluoro-11?-hydroxy-16?-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: May 6, 2014
    Assignee: Taro Pharmaceuticals North America, Inc.
    Inventors: Srinivasa Rao, Suresh Dixit, Avraham Yacobi, Arthur Bailey
  • Patent number: 8716348
    Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: May 6, 2014
    Assignee: Dey Pharma, L.P.
    Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
  • Patent number: 8709385
    Abstract: Pharmaceutical or cosmetic compositions and methods for their use are provided comprising water and a surfactant polymer system comprising a Poloxamer at a concentration of about 0.1% to about 15% by weight; wherein when the Poloxamer is between about 0.1% to about 5% Poloxamer. The composition can further comprise a supporting agent comprising a non-ionic surface active agent or a supporting agent comprising a non surfactant polymer or polysaccharide and an active agent, where the Poloxamer is capable of fixing the composition on delivery to a body surface. There are further provided therapeutic cell compositions and their uses.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: April 29, 2014
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Alex Besonov, Tal Berman, David Schuz, Elana Gazal
  • Patent number: 8703806
    Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 22, 2014
    Assignee: Pearl Therapeutics, Inc.
    Inventors: Reinhard Vehring, Michael Steven Hartman, David Lechuga-Ballesteros, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Jumar Dwivedi
  • Patent number: 8703105
    Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: April 22, 2014
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
  • Publication number: 20140105942
    Abstract: The present invention is directed to an aqueous dispersion comprising: (a) at least one solid wax particle having a particle size ranging from equal to or greater than 1 micron to about 100 microns and comprising at least one wax having a melting point of greater than 35° C.; (b) a surfactant mixture comprising at least one nonionic surfactant and at least one ionic surfactant; and (c) water. The aqueous dispersion may be employed in compositions capable of delivering benefits to various substrates, for example, keratinous substrates such as skin and hair.
    Type: Application
    Filed: October 15, 2012
    Publication date: April 17, 2014
    Applicant: L'Oreal
    Inventors: Bradford Joseph Pistorio, Jean-Thierry Simonnet, Jim M. Singer, Henri Samain
  • Patent number: 8697035
    Abstract: Anhydrous sunscreen compositions that include a volatile solvent, an organic UV-filter dissolved in the volatile solvent, a water-insoluble, low-volatility, C2-C8, liquid silicone dissolved in the volatile solvent, a branched fatty acid ester of a polyprotic carboxylic acid dissolved in the volatile solvent, and a film-forming polymer, where the branched fatty acid ester of a polyprotic carboxylic acid and the water-insoluble, low-volatility, C2-C8, liquid silicone are present in a ratio from about 3:1 to 4.25:1.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: April 15, 2014
    Assignee: Neutrogena Corporation
    Inventor: Laura C. Singleton
  • Patent number: 8679512
    Abstract: Topically administering a propellant-free formulation as a spray in the form of aqueous suspension of drug particles, wherein said formulation consists essentially of: micronized particles of beclometasone dipropionate (BDP) suspended in an aqueous phase, said aqueous phase comprising: an emulsifying agent selected from the class of polysorbates in an amount of 0.1 to 0.2% w/v, based on the total volume of the formulation; a sugar or a sugar alcohol in an amount of 5.0 to 5.2% w/v, based on the total volume of the formulation; a mixture of microcrystalline cellulose and carboxymethylcellulose sodium in an amount of 0.5 to 1.0% w/v, based on the total volume of the formulation; one or more preservatives; and water up to 100%, is effective for the prophylaxis and/or treatment of a dermatological disease such as atopic dermatitis, acne and psoriasis.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: March 25, 2014
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventor: Salvatore Criscione
  • Publication number: 20140079784
    Abstract: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 aerosolized formulations of the present invention.
    Type: Application
    Filed: August 7, 2013
    Publication date: March 20, 2014
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: John Burnier, Thomas Gadek
  • Publication number: 20140079648
    Abstract: An antimicrobial alcoholic foamable composition comprising an alcohol, a waxy component, water, and a dissolvable gas, where the composition is dispensed and foamed without requiring the use of a porous filter, meshed screen, or hazardous propellant.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 20, 2014
    Applicant: GOJO INDUSTRIES, INC.
    Inventor: Mitchell Jared Cohen
  • Patent number: 8668901
    Abstract: Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: March 11, 2014
    Assignee: Activaero GmbH Research & Development
    Inventors: Bernard Muellinger, Gerhard Scheuch, Thomas Hofmann, Philipp Kroneberg
  • Patent number: 8663606
    Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: March 4, 2014
    Assignee: Medigene AG
    Inventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
  • Publication number: 20140056823
    Abstract: A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Thierry BOUYSSOU, Michael P. PIEPER, Andreas SCHNAPP
  • Patent number: 8658138
    Abstract: The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis, as well as for prophylactic and/or cosmetic purposes.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: February 25, 2014
    Assignee: Intendis GmbH
    Inventors: Klaus Graupe, Gerald Städtler
  • Publication number: 20140050673
    Abstract: A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 20, 2014
    Applicant: Foamix Ltd.
    Inventors: Dov Tamarkin, David Schuz, Yohan Hazot, Elana Gazal
  • Patent number: 8653122
    Abstract: An oromucosal formulation containing as an active ingredient a substituted imidazole derivative of formula (I) where Y is —CH2— or —CO—, R1 is halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, or an acid addition salt of this imidazole derivative, and a process for its preparation.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: February 18, 2014
    Assignee: Santhera Pharmaceuticals (Switzerland) Ltd.
    Inventors: Juha-Matti Savola, Päivi Juujärvi, Jukka Ilkka
  • Patent number: 8642069
    Abstract: Viral upper respiratory tract infections, upper respiratory infections, and common colds can be effectively treated by the administration of a combination of a nasal steroid and a nasal antihistamine. By the administration of the combination of a nasal steroid and a nasal antihistamine with the onset of cold symptoms, the histamine cascade and the inflammatory response are impeded or eliminated, reducing the severity, duration, or frequency of the onset of cold symptoms. The combination of a nasal steroid and a nasal antihistamine may be, for example, a physical mixture of the steroid and antihistamine, or it may effectively be a combination wherein the patient is administered one component (either the steroid or the antihistamine) followed by the other, without physical mixing beforehand.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: February 4, 2014
    Inventor: Alexander D. Goldin
  • Publication number: 20140030305
    Abstract: The invention provides for the use of a disinfectant consisting of a mixture of ethanol, 1-propanol and 2-propanol, an antimicrobial, amphoteric surfactant and water for disinfection of display screen surfaces of electronic devices. Mobile communication devices, especially those which are used in the medical sector, have plastic surfaces, more particularly in the form of display screen surfaces. These cannot be disinfected with conventional alcoholic disinfectants. The disinfectant used in accordance with the invention enables effective eradication of microorganisms such as, more particularly, fungi, bacteria and yeasts, with simultaneously good material compatibility.
    Type: Application
    Filed: April 5, 2012
    Publication date: January 30, 2014
    Applicant: BODE CHEMIE GMBH
    Inventors: Barbara Krug, Stephanie Fehling, Richard Bloß
  • Patent number: 8636982
    Abstract: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: January 28, 2014
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Rita Keynan, David Schuz, Tal Berman
  • Patent number: 8636984
    Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: January 28, 2014
    Assignee: Cardeas Pharma Inc.
    Inventor: Alan Bruce Montgomery
  • Patent number: 8636983
    Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: January 28, 2014
    Assignee: Cardeas Pharma Inc.
    Inventor: Alan Bruce Montgomery
  • Publication number: 20140023595
    Abstract: An inhalation device for administering one or more sedatives via pulmonary inhalation for treating a sleep disturbance.
    Type: Application
    Filed: September 12, 2013
    Publication date: January 23, 2014
    Applicant: MAP PHARMACEUTICALS, INC.
    Inventors: Robert Owen Cook, Thomas Armer
  • Patent number: 8633325
    Abstract: Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (Nepeta spp.) such as Nepeta cataria, has been identified as an effective insect repellent compound. Synthesis of dihydronepetalactone may be achieved by hydrogenation of nepetalactone, the major constituent of catmint essential oils. This compound, which also has fragrance properties, may be used commercially for its insect repellent properties, and methods for making an composition thereof are disclosed.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: January 21, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventors: David L. Hallahan, Leo Ernest Manzer
  • Patent number: 8632759
    Abstract: The object of the present invention is to provide a hair restorer which exhibits a stimulatory effect on hair restoration against hair loss, hair thinning, split ends, hair graying, etc., with higher stability and safety than those of known hair restorers containing 5-aminolevulinic acids as active components. By using 5-aminolevulinic acid or its salt or its derivative, and a composition containing iron sodium diethylenetriaminepentaacetate or iron ammonium diethylenetriaminepentaacetate as active components, a hair restorer and a method for restoring hair which are excellent in hair growth promotion, and stability and safety, are provided.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: January 21, 2014
    Assignee: Cosmo Oil Co., Ltd.
    Inventor: Yoshiyasu Ito
  • Patent number: 8629128
    Abstract: A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: January 14, 2014
    Assignee: Stiefel West Coast, LLC
    Inventors: Richard Buchta, Robert James Houlden, Maria Graziella Larm, Leon Loupenok, Rose Ye
  • Patent number: 8623330
    Abstract: Described herein are emulsions and compositions for the treatment of various dermatoses. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. Also described are methods of treating dermatoses, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. The dermatosis may be seborrheic dermatitis.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: January 7, 2014
    Assignee: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Wendy Schilling, Lisa Chin
  • Publication number: 20140004052
    Abstract: The invention provides a method of producing a highly stable pharmaceutical aerosol suspension formulation suitable for use in a metered dose inhaler, the formulation comprising formoterol fumarate di-hydrate in suspension, a steroid in suspension, a propellant and ethanol, the method comprising the steps of drying the formoterol fumarate di-hydrate to a water content of 4.8 to 4.28%.
    Type: Application
    Filed: August 23, 2013
    Publication date: January 2, 2014
    Inventor: Rudi Mueller-Walz
  • Patent number: 8613909
    Abstract: Cinnamic acid-based oligomers and therapeutic uses thereof are provided. The oligomers are used as anti-inflammation agents, inhibitors of elastase and anti-oxidants, and in some cases (e.g. the treatment of lung disorders such as lung cancer) all three activities are simultaneously beneficial. Subsets of the oligomers (e.g. ?-O4 and ?-5 trimers and tetramers) are used as anticoagulants.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: December 24, 2013
    Assignee: Virginia Commonwealth University
    Inventors: Umesh R. Desai, Brian L. Henry, Aiye Liang, Jay Thakkar, John B. Mangrum, Ivo Torres Filho, Bruce D. Spiess, Masahiro Sakagami, Bhawana Saluja
  • Publication number: 20130336900
    Abstract: Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a single surfactant which, in the absence of a solvent, dissolves or disperses the water-insoluble component(s) and provides a homogenous blend in water which provides a stable compressed gas emulsion.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 19, 2013
    Inventors: Richard S. VALPEY, III, Paul A. CLARK, Jessica A. ELWELL (nee HEISER)
  • Patent number: 8609043
    Abstract: The present invention relates to the use of a container, made of an inorganic additive containing plastic material, for reducing physical/chemical interaction between the container and an oil, fat and/or wax containing formulation contained therein.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: December 17, 2013
    Assignee: M & P Patent Aktiengesellschaft
    Inventor: Claudia Mattern
  • Publication number: 20130330282
    Abstract: Spray compositions are formulated with powders (e.g. corn starch) which improve skin feel, and also have a hydrophobically modified oxide additive (e.g. modified silica) to reduce the incidence of can/bottle clogging and sedimentation caused by the powder. The oxide is a mixed hydrophobic/hydrophilic oxide such as hydrophobicly modified fumed silica (e.g. silica dimethyl silylate). In one embodiment DEET can be delivered by such formulations.
    Type: Application
    Filed: June 8, 2012
    Publication date: December 12, 2013
    Inventor: John S. Trent
  • Patent number: 8603439
    Abstract: The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: December 10, 2013
    Assignee: Cardeas Pharma Inc.
    Inventor: Alan Bruce Montgomery
  • Publication number: 20130323183
    Abstract: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.
    Type: Application
    Filed: February 13, 2012
    Publication date: December 5, 2013
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Andrea Pastorello, Devis Galesso, Fabio Bettella
  • Publication number: 20130315998
    Abstract: A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition as a medicament.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicant: CIPLA Limited
    Inventors: Amar Lulla, Geena Malhotra
  • Patent number: 8586007
    Abstract: The use of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant is disclosed. The results have industrial applicability to the development of HFA-based dispersion pressurized metered-dose inhaler formulations.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: November 19, 2013
    Assignee: Wayne State University
    Inventors: Sandro R. P. Da Rocha, Libo Wu
  • Patent number: 8586008
    Abstract: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: November 19, 2013
    Assignee: Stiefel West Coast, LLC
    Inventors: Albert Zorko Abram, Lilian Fuchshuber
  • Publication number: 20130302260
    Abstract: The present invention relates to a novel propellant-gas-containing medicament composition based on tiotropium 1, processes for the preparation thereof and the use of such medicament compositions in the treatment of respiratory complaints.
    Type: Application
    Filed: February 28, 2013
    Publication date: November 14, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bettina BERNER, Hubert HOELZ, Mariola MANN
  • Patent number: 8580282
    Abstract: The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: November 12, 2013
    Assignee: St. Renatus, LLC
    Inventor: Mark David Kollar
  • Publication number: 20130295024
    Abstract: The present invention relates to water-in-oil aerosol emulsion compositions and related methods and, in particular, to aerosol emulsions containing an active agent. In some embodiments, the aerosol emulsion comprises a propellant dissolved in the oil phase.
    Type: Application
    Filed: November 18, 2011
    Publication date: November 7, 2013
    Applicant: Pharmasol Corporation
    Inventor: James Donald Hammer
  • Patent number: 8573198
    Abstract: Methods and devices for creating a supersaturated liquid solution having dissolved gas with hyperbaric partial pressures and aerosolizing the supersaturated solution via a nebulizer. High partial pressures of the dissolved gas may be maintained before, during, and after the aerosolization process. Thus, the hyperbaric partial pressures may be retained in the aerosol particles even after the particles are exposed to ambient barometric pressure. The aerosolized particles may be inhaled to improve oxygenation and blood flow to the lung or alternatively, the aerosolized particles can be topically applied to accelerate wound healing. Nebulizers may produce aerosol particles in some embodiments have mass median aerodynamic diameters of between about 0.25 and about 5 microns, thereby allowing sufficient deposition in the lung parenchyma, proximal to alveoli.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: November 5, 2013
    Assignee: Outcome Solutions, LLC
    Inventors: Johnny Harold Riggs, Daniel J. Grady
  • Patent number: 8569229
    Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: October 29, 2013
    Assignee: The Children's Hospital of Philadelphia
    Inventor: Michael M. Grunstein
  • Patent number: 8568703
    Abstract: Aerosol odor eliminating compositions are described which are aqueous based and include at least one alkylene glycol, at least one surfactant wherein one or more of the at least one surfactant has an HLB of about 7 to about 20, compressed gas propellant, at least one fragrance, a buffering system and water. The composition excludes inclusion of a low molecular weight monohydric. The compositions have a volatile organic content (VOC) of less than 5.0% of the total composition based on 100 wt. %, or alternatively, a VOC of less than 0.1% as to the total composition based on 100 wt. % in absence of the wt. % of the active fragrant material of the fragrance. The compositions additionally have a consistent spray rate at multiple pressure ranges.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: October 29, 2013
    Assignee: S.C. Johnson & Son, Inc.
    Inventors: Peter N. Nguyen, Bhaveshkumar Shah
  • Publication number: 20130280309
    Abstract: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.
    Type: Application
    Filed: May 31, 2013
    Publication date: October 24, 2013
    Inventors: Albert Zorko ABRAM, Lilian FUCHSHUBER